查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1965361

全球醫藥玻璃包裝市場－產業規模、佔有率、趨勢、機會及預測：依產品、藥品類型、地區及競爭格局分類，2021-2031年

Pharmaceutical Glass Packaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Vials, Bottles, Cartridges & Syringes, Ampoules), By Drug Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球醫藥玻璃包裝市場預計將從 2025 年的 210.7 億美元成長到 2031 年的 294.8 億美元，複合年成長率為 5.76%。

該行業的特點是專門生產使用硼矽酸或鈉鈣玻璃製成的初級容器，例如管瓶、安瓿瓶、藥筒和注射器，以確保藥品的無菌性和化學穩定性。市場成長的根本動力來自全球慢性病注射治療需求的不斷上升，以及學名藥行業的蓬勃發展，後者對可靠且受監管的儲存方式提出了更高的要求。除了暫時的市場波動外，這些持續成長要素凸顯了玻璃無與倫比的不滲透性和化學惰性的重要性。這些特性對於保護複雜的生物製藥和疫苗免受環境污染至關重要。

市場概覽
預測期 2027-2031
市場規模：2025年 210.7億美元
市場規模：2031年 294.8億美元
複合年成長率：2026-2031年 5.76%
成長最快的細分市場 瓶子
最大的市場 北美洲

儘管成長前景可觀，但由於玻璃材料本身的易碎性，市場仍面臨許多挑戰。與聚合物替代品相比，玻璃在高速灌裝、表面處理工程中容易破損，導致營運成本增加，安全風險也更高。儘管如此，在主要的高科技製造地區，玻璃產業依然保持著強勁的經濟成長動能。德國玻璃工業協會（Bundesverband Glasindustrie eV）的數據也印證了這種韌性。該協會報告稱，到2024年，對製藥應用至關重要的實用玻璃和特殊玻璃領域的收入將成長6.4%，達到18.2億歐元。

市場促進因素

對需要特殊玻璃的生物製藥和生物相似藥的需求不斷成長，正在推動市場價值鏈的根本性變革，並對先進的密封系統提出了更高的要求。與傳統的小分子藥物不同，單株抗體和GLP-1促效劑等複雜的生物製藥對錶面相互作用高度敏感，因此高品質的I型硼硼矽酸玻璃對於防止分層和確保化學穩定性至關重要。這種需求正促使市場從標準通用管瓶轉向高價值解決方案（HVS），例如預填充式注射器和塗層藥筒，這些產品具有更強的抗破損能力。這種向高階容器的轉變也體現在主要產業參與者的財務表現中。例如，蕭特製藥（SCHOTT Pharma）於2024年12月發布的《2024年度報告》顯示，高價值解決方案的營收成長了22%，占公司總會計收入的55%。

同時，新興經濟體醫藥市場的快速擴張是推動銷售成長的重要因素，與已開發地區以價值驅動的成長形成互補。在政府鼓勵供應鏈本地化的指導指南以及非專利注射劑市場強勁成長的推動下，印度和中國等國正積極擴大其國內醫藥生產能力。這種地理多元化迫使全球玻璃製造商建立本地製造地，以最大限度地降低供應鏈風險並縮短前置作業時間。康寧公司和SGD Pharma的合資企業就是這項策略的顯著例證，Chemindigest在2025年9月對此進行了通報。兩家公司在印度投資500卡羅爾印度盧比，建立了一家生產藥用級硼矽酸玻璃管的工廠。此類投資凸顯了該產業的持續經濟實力，Gerresheimer AG在2025年2月發布的報告也進一步印證了這一點，該報告顯示，其2024會計年度的集團合併收入達到20.4億歐元。

市場挑戰

阻礙醫藥玻璃包裝產業發展的主要障礙在於玻璃材料本身固有的脆弱性。與高耐久性的聚合物替代品相比，玻璃容器在高速填充和表面處理工程中以及物流運輸中極易破損。這種破損會導致昂貴藥物的即時損失，並需要耗費大量成本進行生產線清洗，從而顯著增加營運成本。因此，製造商在運輸易損生物製藥時面臨更高的責任風險，並被迫將玻璃的使用限制在對化學惰性要求絕對嚴格的必要應用中。

這種脆弱性所帶來的經濟影響在市場規模趨勢中得到了清楚的體現。在非專業領域，玻璃容器難以與抗衝擊替代品競爭。此外，微裂紋可能導致顆粒物污染，增加了監管合規的複雜性，限制了其在大規模生產的非專利注射劑領域的應用。玻璃包裝協會2024年的數據顯示，化妝品、藥品和盥洗用品的玻璃容器總合出貨量占美國玻璃容器市場總量的比例仍低於1%，這印證了上述量化限制。這些數據表明，物理特性限制了玻璃容器的應用範圍，使其只能局限於高價值的小眾市場，而無法獲得廣泛的量化優勢。

市場趨勢

即用型 (RTU)管瓶的加速普及最佳化了生產流程，無需內部清潔和滅菌步驟。這一趨勢使得填充和包裝生產線能夠靈活地管理小批量生產，與批量生產相比，從而降低了整體擁有成本。 RTU 平台將包裝準備和藥物填充流程分離，顯著降低了污染風險，並推動了向預滅菌系統的明確過渡。 Stevanato 集團於 2024 年 3 月發布的「2023 年第四季及全年財務表現」清晰地展示了這一轉變，該報告顯示，包括無菌容器系統在內的高價值解決方案的收入成長至占公司總會計收入的 34%。

同時，為支持永續性目標而轉向輕質玻璃設計，強調透過最佳化形狀和使用回收材料來減少碳排放。製造商正在開發熔化和運輸所需能源更少的輕質管瓶，直接有助於實現範圍3的排放目標。這一趨勢支持使用環保玻璃配方，這些配方既滿足企業的ESG要求，又能保持化學穩定性。這種廣泛應用是可以量化的。根據Bormioli Pharma於2024年4月發布的《2023年ESG報告》，該公司已成功將其產品中永續材料的比例提高到45%，比去年同期成長顯著。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球醫藥玻璃包裝市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（管瓶（管瓶、大管瓶）、瓶子（小瓶、大瓶）、卡式注射器/注射器、安瓿瓶）
    • 藥物類型（學名藥、品牌名藥物、生物製藥）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美醫藥玻璃包裝市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲醫藥玻璃包裝市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區醫藥玻璃包裝市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲醫藥玻璃包裝市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲醫藥玻璃包裝市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球醫藥玻璃包裝市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Corning Incorporated
  • Heartsine Technologies, Inc.
  • Nipro Corporation
  • SGD SA
  • Stoelzle Oberglas GmbH
  • Bormioli Pharma SpA
  • West Pharmaceutical Services, Inc.
  • Schott AG
  • Gerresheimer AG
  • Shandong Pharmaceutical Glass Co., Ltd.
  • Beatson Clark
  • Ardagh Group SA
  • Arab Pharmaceutical Glass Co.
  • Piramal Enterprises Ltd.
  • SiSecam Group
  • Owens-Illinois, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23465

The Global Pharmaceutical Glass Packaging Market is projected to expand from USD 21.07 Billion in 2025 to USD 29.48 Billion by 2031, registering a CAGR of 5.76%. This sector is characterized by the specialized production of primary containment vessels, such as vials, ampoules, cartridges, and syringes, utilizing borosilicate or soda-lime glass to guarantee drug sterility and chemical stability. The market's fundamental growth is propelled by the rising global incidence of chronic conditions necessitating injectable treatments and the vigorous development of the generic medicine industry, which demands reliable, regulatory-compliant storage. These enduring drivers, separate from temporary market fluctuations, highlight the essential dependence on glass for its unmatched impermeability and chemical inertness, attributes that are vital for protecting complex biologics and vaccines from environmental contamination.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 21.07 Billion
Market Size 2031USD 29.48 Billion
CAGR 2026-20315.76%
Fastest Growing SegmentBottles
Largest MarketNorth America

Despite this positive growth outlook, the market faces a significant obstacle due to the inherent fragility of the material; glass breakage during high-speed fill-finish processes and transport leads to higher operational costs and safety hazards when compared to polymer substitutes. Nonetheless, the industry sustains robust economic momentum within major high-tech manufacturing territories. This resilience is evidenced by data from the Bundesverband Glasindustrie e.V., which reported that in 2024, the utility and special glass sector-a crucial segment for pharmaceutical uses-saw revenue increase by 6.4 percent, totaling EUR 1.82 billion.

Market Driver

The escalating demand for biologics and biosimilars requiring specialized glass is fundamentally transforming the market's value chain by mandating advanced containment systems. Unlike conventional small-molecule medications, intricate biologics like monoclonal antibodies and GLP-1 agonists exhibit high sensitivity to surface interactions, necessitating high-quality Type I borosilicate glass to avoid delamination and guarantee chemical stability. This necessity has driven a migration from standard commoditized vials toward High-Value Solutions (HVS), such as prefilled syringes and coated cartridges, which provide enhanced inertness and resistance to breakage. The pivot toward premium containment is reflected in the financial results of leading industry players; for example, SCHOTT Pharma's 'Annual Report 2024', released in December 2024, noted that revenue from high-value solutions rose by 22 percent, comprising 55 percent of its total fiscal revenue.

Concurrently, the rapid expansion of pharmaceutical markets in emerging economies serves as a crucial volume driver, complementing the value-focused growth seen in developed regions. Nations like India and China are aggressively building domestic pharmaceutical manufacturing capacities, aided by government directives for supply chain localization and the strong growth of the generic injectables market. This geographic diversification forces global glass producers to create local manufacturing centers to minimize supply chain risks and shorten lead times. A prominent instance of this strategy is cited by Chemindigest in September 2025, detailing a joint venture between Corning Incorporated and SGD Pharma to open a facility in India with an INR 500 crore investment for producing pharmaceutical-grade borosilicate glass tubing. Such investments highlight the sector's ongoing economic strength, further supported by Gerresheimer AG's February 2025 report, which announced consolidated group revenues of EUR 2.04 billion for the 2024 financial year.

Market Challenge

The principal obstacle hindering the growth of the pharmaceutical glass packaging industry is the material's intrinsic fragility. In contrast to durable polymer alternatives, glass containers are prone to fracturing during intense high-speed fill-finish operations and logistical handling. Such breakage causes the immediate loss of expensive drug formulations and mandates expensive production halts for line clearance, thereby substantially increasing operational costs. As a result, manufacturers confront increased liability risks when transporting delicate biologics, forcing them to restrict glass utilization to essential applications where chemical inertness is absolute and non-negotiable.

The economic repercussions of this vulnerability are apparent in market volume trends, where glass faces difficulty competing with shatter-resistant substitutes in non-specialized categories. The potential for particulate contamination arising from micro-cracks further adds to regulatory compliance complexities, limiting adoption within the mass-market generic injectables sector. Underscoring this volume constraint, data from the Glass Packaging Institute in 2024 indicated that the combined shipment share for cosmetics, pharmaceuticals, and toiletries accounted for less than 1 percent of the total United States glass container market. This statistic demonstrates how physical limitations restrict the material to a high-value niche, precluding it from achieving broader dominance in volume.

Market Trends

The accelerating adoption of sterile Ready-to-Use (RTU) glass vials is optimizing manufacturing processes by removing the need for in-house washing and sterilization. This trend enables fill-finish lines to manage smaller batch sizes with enhanced flexibility, thereby lowering the total cost of ownership relative to bulk processing. By separating packaging preparation from drug filling, RTU platforms significantly reduce contamination risks, driving a definitive move toward pre-sterilized systems. This transition is highlighted by the Stevanato Group's 'Fourth Quarter and Full Year 2023 Financial Results' from March 2024, which reported that revenue from the high-value solutions segment, encompassing sterile containment systems, grew to represent 34 percent of the company's total fiscal revenue.

Simultaneously, the shift toward lightweight glass designs to support sustainability goals is emphasizing carbon reduction through the use of optimized geometries and recycled materials. Manufacturers are developing lighter vials that demand less energy for melting and transportation, directly contributing to meeting Scope 3 emission targets. This movement validates the use of eco-friendly glass formulations that retain chemical stability while satisfying corporate ESG requirements. The extent of this adoption is quantifiable; as per Bormioli Pharma's 'ESG Report 2023' released in April 2024, the company successfully raised the proportion of sustainable materials in its sold products to 45 percent, indicating a substantial expansion compared to the previous year.

Key Market Players

  • Corning Incorporated
  • Heartsine Technologies, Inc.
  • Nipro Corporation
  • SGD S.A.
  • Stoelzle Oberglas GmbH
  • Bormioli Pharma S.p.A.
  • West Pharmaceutical Services, Inc.
  • Schott AG
  • Gerresheimer AG
  • Shandong Pharmaceutical Glass Co., Ltd.
  • Beatson Clark
  • Ardagh Group S.A
  • Arab Pharmaceutical Glass Co.
  • Piramal Enterprises Ltd.
  • SiSecam Group
  • Owens-Illinois, Inc.

Report Scope

In this report, the Global Pharmaceutical Glass Packaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Glass Packaging Market, By Product

  • Vials (Small vials, Large vials)
  • Bottles(Small bottles, Large bottles)
  • Cartridges & Syringes
  • Ampoules

Pharmaceutical Glass Packaging Market, By Drug Type

  • Generic
  • Branded
  • Biologic

Pharmaceutical Glass Packaging Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Glass Packaging Market.

Available Customizations:

Global Pharmaceutical Glass Packaging Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Glass Packaging Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Vials (Small vials, Large vials), Bottles(Small bottles, Large bottles), Cartridges & Syringes, Ampoules)
    • 5.2.2. By Drug Type (Generic, Branded, Biologic)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Pharmaceutical Glass Packaging Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Drug Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmaceutical Glass Packaging Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Drug Type
    • 6.3.2. Canada Pharmaceutical Glass Packaging Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Drug Type
    • 6.3.3. Mexico Pharmaceutical Glass Packaging Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Drug Type

7. Europe Pharmaceutical Glass Packaging Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Drug Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmaceutical Glass Packaging Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Drug Type
    • 7.3.2. France Pharmaceutical Glass Packaging Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Drug Type
    • 7.3.3. United Kingdom Pharmaceutical Glass Packaging Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Drug Type
    • 7.3.4. Italy Pharmaceutical Glass Packaging Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Drug Type
    • 7.3.5. Spain Pharmaceutical Glass Packaging Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Drug Type

8. Asia Pacific Pharmaceutical Glass Packaging Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Drug Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharmaceutical Glass Packaging Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Drug Type
    • 8.3.2. India Pharmaceutical Glass Packaging Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Drug Type
    • 8.3.3. Japan Pharmaceutical Glass Packaging Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Drug Type
    • 8.3.4. South Korea Pharmaceutical Glass Packaging Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Drug Type
    • 8.3.5. Australia Pharmaceutical Glass Packaging Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Pharmaceutical Glass Packaging Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Drug Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharmaceutical Glass Packaging Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Drug Type
    • 9.3.2. UAE Pharmaceutical Glass Packaging Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Drug Type
    • 9.3.3. South Africa Pharmaceutical Glass Packaging Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Drug Type

10. South America Pharmaceutical Glass Packaging Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Drug Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmaceutical Glass Packaging Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Drug Type
    • 10.3.2. Colombia Pharmaceutical Glass Packaging Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Drug Type
    • 10.3.3. Argentina Pharmaceutical Glass Packaging Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharmaceutical Glass Packaging Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Corning Incorporated
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Heartsine Technologies, Inc.
  • 15.3. Nipro Corporation
  • 15.4. SGD S.A.
  • 15.5. Stoelzle Oberglas GmbH
  • 15.6. Bormioli Pharma S.p.A.
  • 15.7. West Pharmaceutical Services, Inc.
  • 15.8. Schott AG
  • 15.9. Gerresheimer AG
  • 15.10. Shandong Pharmaceutical Glass Co., Ltd.
  • 15.11. Beatson Clark
  • 15.12. Ardagh Group S.A
  • 15.13. Arab Pharmaceutical Glass Co.
  • 15.14. Piramal Enterprises Ltd.
  • 15.15. SiSecam Group
  • 15.16. Owens-Illinois, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer